Related Experiment Video
Updated: May 14, 2025
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
BAAT away liver cancer: conjugated bile acids impair T cell function in hepatocellular carcinoma immunotherapy
Zachary Detwiler1, Snehal N Chaudhari2
1Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, USA.
Abstract:
In this renaissance era of gene therapy, a new study published by the Susan Kaech lab in Science demonstrates the use of CRISPR-Cas9 technology to selectively deplete conjugated bile acids in the liver by targeting the bile acid-CoA:amino acid N-acyltransferase (Baat) gene to improve responsiveness to immunotherapy. This study highlights the role of conjugated bile acids in impairing intratumoral T cell function by directly accumulating in resident liver T cells and driving mitochondrial dysfunction. Knockout of Baat reduced hepatic conjugated bile acid production, thus improving immunotherapy potency and reducing tumor burden. Subsequently, Baat liver knockout reduced levels of microbially produced secondary bile acids such as lithocholic acid, a known carcinogen and T cell toxin. This study mechanistically links bile acids to liver cancer immunotherapy success, setting the stage for bile acid-based screening approaches and pharmacologic manipulations for improved patient outcomes.
Insights
Gene therapy using CRISPR-Cas9 to deplete liver bile acids by targeting the Baat gene enhances cancer immunotherapy. This approach improves T cell function and reduces tumor burden, offering new strategies for patient treatment.
Area of Science:
- Immunology
- Genetics
- Hepatology
Background:
- Conjugated bile acids accumulate in liver T cells, impairing their function and driving mitochondrial dysfunction.
- This accumulation negatively impacts the effectiveness of cancer immunotherapy in the liver.
Purpose of the Study:
- To investigate the role of conjugated bile acids in immunotherapy resistance.
- To explore the therapeutic potential of depleting bile acids in liver cancer treatment.
Main Methods:
- Utilized CRISPR-Cas9 gene editing to selectively knock out the bile acid-CoA:amino acid N-acyltransferase (Baat) gene in the liver.
- Assessed the impact of Baat knockout on hepatic conjugated bile acid levels, T cell function, and immunotherapy response in a tumor model.
Main Results:
- Baat knockout significantly reduced hepatic conjugated bile acid production.
- This reduction improved intratumoral T cell function and enhanced immunotherapy potency, leading to decreased tumor burden.
- Reduced levels of toxic secondary bile acids like lithocholic acid were observed.
Conclusions:
- Targeting the Baat gene to deplete conjugated bile acids is a viable strategy to overcome immunotherapy resistance in liver cancer.
- This study mechanistically links bile acids to immunotherapy outcomes, paving the way for novel therapeutic interventions.
More Related Videos
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:40Cell-mediated Immune Responses